CEBPB and myocarditis: Neutralization of OSM in vivo reproduced much of rapamycin's protective phenotype, nominating the mTORC1–C/EBPβ–OSM pathway as a central therapeutic axis in myocarditis and chronic inflammatory cardiomyopathy.